Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Novartis AG (NVS) Price & Performance

BBVA trades at $28.545, up 0.69% today, with a bullish technical signal from moving averages but overbought RSI readings. The bank reported strong Q2 2026 earnings, beating estimates with an 11.4% net profit rise, and announced a $2.3 billion share buyback. Revenue growth has been steady, reaching $39.42 billion in 2025, with a net income margin of 26.13% and ROE of 18.5%, though valuation ratios like P/E of 12.98 and P/S of 3.27 suggest moderate pricing.

Outlook remains positive with analyst consensus at 53.85% buy ratings, driven by profitability improvements and strategic initiatives. Key risks include regulatory probes in Spain and antitrust investigations, which could impact sentiment. Investors should weigh solid fundamentals against legal uncertainties for balanced exposure.

Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.

The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.